Event Date/Time: Feb 01, 2010 End Date/Time: Feb 02, 2010
Registration Date: Feb 01, 2010
Early Registration Date: Oct 15, 2010
Report as Spam


Now in its second year, Vaccine Innovation is following the development of the vaccine industry as it emerges from a staid market due to lack of innovation or pipeline development.

The current spectre of global pandemics such as bird and swine flu, government-led incentives and advances in technology are revitalising the market giving the pharmaceutical industry a renewed interest in vaccine development.

With technological advances and more investment becoming available, there is renewed interest in bolstering pharmaceutical pipelines with vaccine innovations and technologies. There has never been a better time to become involved in innovative vaccine technologies.

Why attend?
Attend Vaccine Innovation and:

Learn new ways to identify and validate new adjuvants for enhanced immune response
Hear the latest clinical developments on vaccines such as HPV, RSV, Hep B
Understand how to improve the relationships between academia/biotech and large pharmaceutical companies to aid vaccine development
Learn the latest development in vaccine delivery and manufacturing
Who should attend?
Vaccine Innovation is a leading meeting of international scientists and research leaders from the vaccine industry ranging from academia and research institutes to biotechs and pharmaceutical companies. Directors and Heads of Vaccine R&D, Chief Executives, Scientific Officers and Heads of Commercialisation will have the opportunity to debate and discuss the key issues concerning vaccine research and development.

The agenda will cover:
Key factors driving vaccine development
Global policy and emerging markets
Innovation vs. regulation: Novel technologies in delivery and adjuvant systems - a key factor to novel vaccines
Collaboration and funding - the key to successful vaccine innovation
Funding and investment - an investors perspective
Adjuvant and delivery systems for enhanced immune response
Enhancing the efficacy of vaccine adjuvants
Vaccine delivery systems
Clinical updates on: RSV, CNV, Herpes, Hep B and HPV